Fjarde AP Fonden Fourth Swedish National Pension Fund increased its holdings in Iqvia Holdings Inc (NYSE:IQV) by 62.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,770 shares of the medical research company’s stock after purchasing an additional 19,138 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Iqvia were worth $4,968,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Farallon Capital Management LLC grew its stake in Iqvia by 6.6% during the first quarter. Farallon Capital Management LLC now owns 3,158,647 shares of the medical research company’s stock worth $309,895,000 after buying an additional 195,703 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in Iqvia by 39.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,214,074 shares of the medical research company’s stock worth $119,113,000 after buying an additional 341,692 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Iqvia by 0.8% during the first quarter. Schwab Charles Investment Management Inc. now owns 575,608 shares of the medical research company’s stock worth $56,473,000 after buying an additional 4,570 shares during the last quarter. Bloom Tree Partners LLC grew its stake in Iqvia by 39.7% during the first quarter. Bloom Tree Partners LLC now owns 525,562 shares of the medical research company’s stock worth $51,563,000 after buying an additional 149,398 shares during the last quarter. Finally, Morningstar Investment Services LLC grew its stake in Iqvia by 11.3% during the first quarter. Morningstar Investment Services LLC now owns 463,285 shares of the medical research company’s stock worth $45,453,000 after buying an additional 47,079 shares during the last quarter. 89.83% of the stock is owned by hedge funds and other institutional investors.

In related news, Director John Connaughton sold 1,441,236 shares of the stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $103.00, for a total value of $148,447,308.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Ari Bousbib sold 92,160 shares of the stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $103.20, for a total transaction of $9,510,912.00. The disclosure for this sale can be found here. Insiders sold 10,824,432 shares of company stock worth $1,114,934,928 over the last 90 days. 6.00% of the stock is currently owned by company insiders.

Several analysts have weighed in on IQV shares. ValuEngine raised shares of Iqvia from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. Zacks Investment Research raised shares of Iqvia from a “hold” rating to a “buy” rating and set a $111.00 price objective on the stock in a research note on Wednesday, July 4th. Goldman Sachs Group raised shares of Iqvia from a “neutral” rating to a “buy” rating in a research note on Friday, April 13th. Argus upped their price objective on shares of Iqvia from $110.00 to $112.00 and gave the stock a “buy” rating in a research note on Monday, April 9th. Finally, Robert W. Baird raised shares of Iqvia from a “neutral” rating to an “outperform” rating in a research note on Monday, June 18th. Five equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $110.41.

IQV opened at $109.00 on Wednesday. Iqvia Holdings Inc has a one year low of $87.45 and a one year high of $110.67. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 1.22. The company has a market cap of $22.13 billion, a PE ratio of 25.00, a P/E/G ratio of 1.79 and a beta of 0.62.

Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, May 2nd. The medical research company reported $1.34 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.27 by $0.07. Iqvia had a net margin of 13.07% and a return on equity of 13.35%. The business had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Iqvia’s revenue for the quarter was up 34.1% compared to the same quarter last year. equities analysts anticipate that Iqvia Holdings Inc will post 5.07 EPS for the current fiscal year.

Iqvia Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: What is a closed-end mutual fund (CEF)?

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.